Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics Q3 net loss $111.4 million; CASGEVY revenue $99 million

Mixed Impact 3 of 5 earnings Written later

CRISPR Therapeutics reported third quarter 2026 results, with total revenue of $12.7 million versus $0.9 million a year earlier and a net loss of $111.4 million versus $106.4 million. The company said CASGEVY revenue reached $99 million, and cash and marketable securities totaled $2,276.6 million at September 30, 2026, which shareholders may weigh against the continued losses.

Key points

  • Total revenue was $12.7 million for Q3 2026, compared with $0.9 million for Q3 2025.
  • Net loss was $111.4 million, or $1.15 per share, versus a net loss of $106.4 million, or $1.17 per share, a year earlier.
  • CASGEVY revenue was $99 million in Q3 2026, up 30% quarter-over-quarter.
  • Cash, cash equivalents, and marketable securities were $2,276.6 million as of September 30, 2026.

The filing

CompanyCRISPR Therapeutics AG (CRSP)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:07 PM ET
Accession number0001193125-26-443644

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.